The role of surface molecule CD229 in Multiple Myeloma.

[1]  P. Engel,et al.  Targeting of Ly9 (CD229) Disrupts Marginal Zone and B1 B Cell Homeostasis and Antibody Responses , 2016, The Journal of Immunology.

[2]  M. Boccadoro,et al.  Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents , 2016, Cytometry. Part B, Clinical cytometry.

[3]  A. Órfão,et al.  Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases , 2016, Cytometry. Part B, Clinical cytometry.

[4]  Marion H. Brown,et al.  A polymorphism in a phosphotyrosine signalling motif of CD229 (Ly9, SLAMF3) alters SH2 domain binding and T‐cell activation , 2015, Immunology.

[5]  A. Azzará,et al.  CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance , 2015, Acta Haematologica.

[6]  J. Panse,et al.  CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma , 2015, Human vaccines & immunotherapeutics.

[7]  A. Palumbo,et al.  Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival , 2014, Leukemia.

[8]  P. Engel,et al.  Ly9 (CD229) Cell-Surface Receptor is Crucial for the Development of Spontaneous Autoantibody Production to Nuclear Antigens , 2013, Front. Immunol..

[9]  G. Morgan,et al.  Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Dimopoulos,et al.  Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. , 2012, Blood.

[11]  I. Weissman,et al.  CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells , 2012, Leukemia.

[12]  J. Spencer,et al.  Translational Mini‐Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell‐targeted therapies , 2012, Clinical and experimental immunology.

[13]  C. Mitsiades,et al.  Autologous stem cell transplantation and multiple myeloma cancer stem cells. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  C. Bokemeyer,et al.  Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma , 2011, Haematologica.

[15]  P. Engel,et al.  Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells. , 2011, Immunology letters.

[16]  J. Brieva,et al.  Differential expression of SLAMS and other modulatory molecules by human plasma cells during normal maturation. , 2011, Immunology letters.

[17]  A. Palumbo,et al.  Multiple myeloma. , 2011, The New England journal of medicine.

[18]  M. Boccadoro,et al.  Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Órfão,et al.  Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. , 2008, Blood.

[20]  T. Hudson,et al.  Association of LY9 in UK and Canadian SLE families , 2008, Genes and Immunity.

[21]  R. Braylan,et al.  Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study , 2008, Leukemia & lymphoma.

[22]  P. Pizcueta,et al.  CD229 (Ly9) Lymphocyte Cell Surface Receptor Interacts Homophilically through Its N-Terminal Domain and Relocalizes to the Immunological Synapse 1 , 2005, The Journal of Immunology.

[23]  P. Engel,et al.  Identification of Grb2 As a Novel Binding Partner of the Signaling Lymphocytic Activation Molecule-Associated Protein Binding Receptor CD229 1 , 2005, The Journal of Immunology.

[24]  R. Vilella,et al.  Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). , 2004, Tissue antigens.

[25]  M. Eck,et al.  SAP increases FynT kinase activity and is required for phosphorylation of SLAM and Ly9. , 2004, International immunology.

[26]  P. Engel,et al.  The Cell Surface Expression of SAP-binding Receptor CD229 Is Regulated via Its Interaction with Clathrin-associated Adaptor Complex 2 (AP-2)* , 2003, The Journal of Biological Chemistry.

[27]  Xuejun Jiang,et al.  Grb2 regulates internalization of EGF receptors through clathrin-coated pits. , 2003, Molecular biology of the cell.

[28]  Massimo Morra,et al.  Structural basis for the interaction of the free SH2 domain EAT‐2 with SLAM receptors in hematopoietic cells , 2001, The EMBO journal.

[29]  P. Engel,et al.  Cell surface receptors Ly-9 and CD84 recruit the X-linked lymphoproliferative disease gene product SAP. , 2001, Blood.

[30]  N. Villamor,et al.  Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9. , 2001, Blood.

[31]  K. Blenman,et al.  Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  B. Croker,et al.  Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. , 1999, The Journal of clinical investigation.

[33]  M. Moran,et al.  Requirement for the Adapter Protein GRB2 in EGF Receptor Endocytosis , 1996, Science.